Growth inhibitory effects of quercetin on bladder cancer cell

Frontiers in Bioscience

Volumn 11, Issue SUPPL. 1, 2006, Pages 2275-2285

  Ma, Li ^a   Feugang, Jean Magloire ^b   Konarski, Patricia ^b   Wang, Jian ^b   Lu, Jianzhong ^a   Fu, Shengjun ^a   Ma, Baoliang ^a   Tian, Binqiang ^a   Zou, Changping ^b   Wang, Zhingping ^a  

^a LANZHOU UNIVERSITY   (China)

^b UNIVERSITY OF ARIZONA   (United States)

Author keywords

Apoptosis; Bladder cancer; Cell cycle; DNA methylation; Er beta; p21; PTEN; Quercetin; RASSF1A

Indexed keywords

ANIMALIA;

EID: 33744776293     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/1970     Document Type: Article

References (58)

1. Cancer facts and figures: American Cancer Society Inc., Surveillance Research (2003)
2. Jones P. A. and S. B. Baylin: The fundamental role of epigenetic events in cancer. Nat Rev Genet 3, 415-428 (2002)
3. Herman J.G. and S. B. Baylin: Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 349, 2042-2054 (2003)
4. Herr H. W., D. D. Wartinger, W. R. Fair and H. F. Oettgen: Bacillus Calmette-Guerin therapy for superficial bladder cancer: a 10-year follow-up. J Urol 147, 1020-1023 (1992)
5. Lamm D. L., D. E. Thor, S. C. Harris, J. A. Reyna, V. D. Stogdill and H. M. Radwin: Bacillus Calmette-Guerin immunotherapy of superficial bladder cancer. J Urol 124, 38-40 (1980)
6. Elattar T. M. and A. S. Irji: The effect of red wine and its components on growth and proliferation on human oral squamous carcinoma cells. Anticancer Res 9, 5407-5414 (1999)
7. Richer M., R. Ebermann and B. Marian: Quercetin - induced apoptosis I colorectal tumor cells: possible role of ECG receptor signaling. Nutr Cancer 34, 88-89 (1999)
8. Deschner E. E., J. Ruperto, G. Wong and H. L. Newmark: Quercetin and rutin as inhibitors of azoxymethanol-induced colonic neoplasia. Carcinogenesis 12, 1193-1196 (1991)
9. Naji N. M., M. A. Carothors, D. Grunberger, R. T. Billinski, M. R. Churchill, C. Martacci, H. L, Newark and M. M. Bertagndl: Plant phenolics decrease intestinal tumor in an animal model of familial adenomatas polyposis. Carcinogenesis 21, 921-927 (2000)
10. Avila M. A., J. A. Velasco, J. Cansado and V. Notario: Quercetin mediates the down-regulation of mutant p53 in the human breast cancer cell line MDA-MB468. Cancer Res 54, 2424-2428 (1994)
11. Plaumann B., M. Pritsche, H. Rimpler, G. Brandner and R. D. Hess: Flavonoids activate wild-type p53. Oncogene 13, 1605-1614 (1996)
12. Ferrandina G., G. Almadori, N. Maggiano, P. Lanza, C. Ferlini, P. Cattani, M. Piantelli, G. Scambia and F. O. Ranelletti: Growth-inhibitory effect of tamoxifen and quercetin and presence of type II estrogen binding sites in human laryngeal cancer cell lines and primary laryngeal tumors. Int J Cancer 77, 747-754 (1998)
13. Ranelletti F. O., R. Ricci and L. M. Larocca: Growth-inhibitory effect of quercetin and presence of type-II estrogen-binding sites in human colon-cancer cell lines and primary colorectal tumors. Int J Cancer 50, 486-492 (1992)
14. Yoshida M., M. Yamamoto and T. Nikaido: Quercetin arrests human leukemic T-cells in late G1 phase of the cell cycle. Cancer Res 52, 6676-6681, (1992)
15. Ong C. S., E. Tran, T. T. Nguyen, C. K. Ong, S. K. Lee, J. J. Lee, C. P. Ng, C. Leong, and H. Huynh: Quercetin-induced growth inhibition and cell death in nasopharyngeal carcinoma cells are associated with increase in Bad and hypophosphorylated retinoblastoma expressions. Oncol Rep 11, 727-733, (2004)
16. Gupta K. and D. Panda: Perturbation of microtubule polymerization by quercetin through tubulin binding: a novel mechanism of its antiproliferative activity. Biochemistry 41, 13029-13038 (2002)
17. Yoshizumi M., K. Tsuchiya, K. Kirima, M. Kyaw, Y. Suzaki and T. Tamaki: Quercetin inhibits She- and phosphatidylinositol 3-kinase-mediated c-Jun N-terminal kinase activation by angiotensin II in cultured rat aortic smooth muscle cells. Mol Pharmacol 60, 656-665 (2001)
18. Bates S. and K. H. Vousden: p53 in signaling checkpoint arrest or apoptosis. Curr Opin Genet Dev 6, 12-18 (1996)
19. Levine A. J.: p53, the cellular gatekeeper for growth and division. Cell 88, 323-331 (1997)
20. Hofseth L. J., S. P. Hussain and C. C. Harris: p53: 25 years after its discovery. Trends Pharmacol Sci 25, 177-181 (2004)
21. Smith M. L., I. T. Chen, Q. Zhan, P. M. O'Connor and A. J. Jr Fornace: Antisense GADD45 expression results in decreased DNA repair and sensitizes cells to uv-irradiation or cisplatin. Oncogene 10, 1053-1059 (1995)
22. Motoyama N. and K. Naka: DNA damage tumor suppressor genes and genomic instability. Curr Opin Genet Dev 14, 11-16 (2004)
23. Agarwal M. L., A. Agarwal, W. R. Taylor, and G. R. Stark: p53 controls both the G2/M and the G1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts. Natl Acad Sci 92, 8493-8497 (1995)
24. Fujimoto K., Y. Yaraada, E. Okajima, T. Kakizoe, H. Sasaki, T. Sugimura and M. Terada: Frequent association of p53 gene mutation in invasive bladder cancer. Cancer Res 52, 1393-1398 (1992)
25. Slaton J. W., W. F. Benedict and C. P. Dinney: p53 in bladder cancer: mechanism of action, prognostic value, and target for therapy. Urology 57, 852-859 (2001)
26. Ambrosini G., C. Adida and D. C. Altieri: Survivin gene expression and prognosis in recurrent colorectal cancer. Nat Med 3, 917-921 (1997)
27. Li F., G. Ambrosini, E. Y. Chu, J. Plescia, S. Tognin, P. C. Marchisio and D. C. Altieri: Control of apoptosis and mitotic spindle checkpoints by survivin. Nature 396, 580-584 (1998)
28. Chao J. L, P. C. Kuo and T. S. J. Hsu: Down-regulation of Survivin in Nitric Oxide-induced Cell Growth Inhibition and Apoptosis of the Human Lung Carcinoma Cells. Biol Chem 279, 20267-20276 (2004)
29. Beltrami E., J. Plescia, J. C. Wilkinson, C. S. Duckett and D. C. J. Altieri: Survivin is required for stable checkpoint activation in taxol-treated HeLa cells. Biol Chem 279, 2077-2084 (2004)
30. Kawamura K., N. Sato, J. Fukuda, H. Kodama, J. Kumagai, H. Tanikawa, Y. Shimizu and T. Tanaka: Survivin acts as an antiapoptotic factor during the development of mouse preimplantation embryos. Dev Biol 256, 331-341 (2003)
31. Wall N. R., D. S. O'Connor, J. Plescia, Y. Pommier and D. C. Altieri: Suppression of survivin phosphorylation on Thr34 by flavopiridol enhances tumor cell apoptosis. Cancer Res 63, 230-235 (2003)
32. O'Connor D. S., D. Grossman, J. Plescia, F. Li, H. Zhang, A. Villa, S. Tognin, P. C. Marchisio and D. C. Altieri: Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin. Proc Natl Acad Sci 97, 13103-13107 (2000)
33. Wright W. E., O. M. Pereira-Smith and J. W. Shay: Reversible cellular senescence: implications for immortalization of normal human diploid fibroblasts. Mol Cell Biol 9, 3088-3092 (1989)
34. Van Rijn J. and J. van den Berg: Flavonoids as enhancers of X-ray induced cell damage in hepatoma cells. Clin Cancer Res 3, 1775-1779 (1997)
35. Ross R., J.-M. Yuan, G. N. Wogan, G.-S. Qian, J.-T. Tu, J. D. Groopman, Y.-T. Gao and B. E. Henderson: Urinary aflatoxin biomarkers and risk of hepatocellular carcinoma. Lancet 339, 943-946 (1992)
36. Nair H. K., K. V. K. Rao, R. Aalinkeel, S. Mahajan, R. Chawda and S. A. Schwartz: Inhibition of prostate cancer cell colony formation by the flavonoid quercetin correlates with modulation of specific regulatory gene. Clinical and Diagnosic Laboratory Immunology 11, 63-69 (2004)
37. Herman J. G., J. R. Graff, S. Myohanen, B. D. Nelkin and S. B. Baylin: Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci 93, 9821-9826 (1996)
38. Young J. F., S. E. Nielsen, J. Haraldsdottir, B. Daneshvar, S. T. Lauridsen, P. Knuthsen, A. Crozier, B. Sandstrom and L. O. Dragsted: Effect of fruit juice intake on urinary quercetin excretion and biomarkers of antioxidative status. Am J Clin Nutr 69, 87-94 (1999)
39. Block G., B. Patterson and A. Subar: Fruit, vegetables, and cancer prevention: a review of the epidemiological evidence. Nutr Cancer 18, 1-29 (1992)
40. Nguyen T. T. T., E. Tran, T. H. Nguyen, P. T. Do, T. H. Huynh and H. Huynh: The role of activated MEK-ERK pathway in quercetin-induced growth inhibition and apoptosis in A549 lung cancer cells. Carcinogenesis 25, 647-659 (2004)
41. Zhou J. R., P. Mukherjee, E. T. Gugger, T. Tanaka, G. L. Blackburn and S. K. Clinton: Inhibition of murine bladder tumorigenesis by soy isoflavones via alterations in the cell cycle, apoptosis, and angiogenesis. Cancer Res 58, 5231-5238 (1998)
42. Shao Z. M., J. Wu, Z. Z. Shen and S. H. Barsky: Genistein exerts multiple suppressive effects on human breast carcinoma cells. Cancer Res 58, 4851-4857 (1998)
43. Wang H. K.: The therapeutic potential of flavonoids. Expert Opin Investig Drugs 9, 2103-2119 (2000)
44. Slaton J. W., W. F. Benedict and C. P. Dinney: p53 in bladder cancer: mechanism of action, prognostic value, and target for therapy. Urology 57, 852-859 (2001)
45. Avila M. A., J. A. Velasco, J. Cansado and V. Notario: Quercetin mediates the down-regulation of mutant p53 in the human breast cancer cell line MDA-MB468. Cancer Res 54, 2424-2428 (1994)
46. Altieri D. C.: Validating survivin as a cancer therapeutic target. Nat Rev Cancer 3, 46-54 (2003)
47. Li J., C. Yen, D. Liaw, K. Podsypanina, S. Bose, S. L. Wang, J. Pue, C. Miliaresis, L. Rodgers, R. McCombie and R. Pararsons: PTEN a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275, 1943-1947 (1997)
48. Steck P. A., M. A. Pershouse, S. A. Jasser, W. K. A. Yung, H. Lin, A. H. Ligon, L. A. Langford, M. L. Baumgard, T. Hattier, T. Davis, C. Frye, R. Hu, B. Swedlund, D. H. F. Teng and S. V. Tavtigian. Identification of a candidate tumor suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 15, 356-362 (1997)
49. McNeish I. A., S. J. Bell and N. R. Lemoine: Gene therapy progress and prospects: cancer gene therapy using tumor suppressor genes. Gene Ther 11, 497-503 (2004)
50. Munoz J., P. Lazcoz, M. M. Inda, M. Nistal, A. Pestana, I. J. Encio and J. S. Castresana: Homozygous deletion and expression of PTEN and DMBT1 in human primary neuroblastoma and cell lines. Int J Cancer 109, 673-679 (2004)
51. Guldberg P., Strafen, A. Birck, V. Ahrenkiel, A. F. Kirkin and J. Zeuthen: Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma. Cancer Res 57, 3660-3663 (1997)
52. Smith J. S., I. Tachibana, S. M. Passe, B. K. Huntley, T. J. Borell, N. Iturria, J. R. O'Fallon, P. L. Schaefer, B. W. Scheithauer, C. D. James, J. C. Buckner and R. B. Jenkins: PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst 93, 1246-56 (2001)
53. Young E. W., X. Wu, H. Suzuki, R. E. Reiter, C. Tran, R. L. Vessella, J. W. Said, W. B. Isaacs and C. L. Sawyers: Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Nat. Genet 17, 143-144 (1997)
54. Richardson B. and R. Yung: Role of DNA methylation in the regulation of cell fonction. J Lab Clin Med 134, 333-340 (1999)
55. Laird P. W. and R. Jaenisch: DNA methylation and cancer. Hum Mol Genet 3, 1487-1495 (1994)
56. Miyamoto K. and T. Ushijima: Diagnostic and therapeutic applications of epigenetics. Japan J Clinical Oncol 35, 293-301 (2005)
57. Pfeifer G. P., J. H. Yoon, L. Liu, S. Tommasi, S. P. Wilczynski, R. Dammann: Methylation of the RASSF1A gene in human cancers. Biol Chem 383, 907-914 (2002)
58. Li L. C., P. R. Carroll and R. Dahiya: Epigenetic changes in prostate cancer: Implication for diagnosis and treatment. J Natl Cancer Inst 97, 103-115 (2005)